annual EBITDA:
$29.12M-$125.47M(-81.16%)Summary
- As of today (July 1, 2025), PCRX annual EBITDA is $29.12 million, with the most recent change of -$125.47 million (-81.16%) on December 31, 2024.
- During the last 3 years, PCRX annual EBITDA has fallen by -$84.83 million (-74.45%).
- PCRX annual EBITDA is now -81.16% below its all-time high of $154.59 million, reached on December 31, 2023.
Performance
PCRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$33.61M-$16.99M(-33.58%)Summary
- As of today (July 1, 2025), PCRX quarterly EBITDA is $33.61 million, with the most recent change of -$16.99 million (-33.58%) on March 31, 2025.
- Over the past year, PCRX quarterly EBITDA has dropped by -$1.09 million (-3.15%).
- PCRX quarterly EBITDA is now -44.06% below its all-time high of $60.08 million, reached on June 30, 2023.
Performance
PCRX quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$28.03M-$1.09M(-3.75%)Summary
- As of today (July 1, 2025), PCRX TTM EBITDA is $28.03 million, with the most recent change of -$1.09 million (-3.75%) on March 31, 2025.
- Over the past year, PCRX TTM EBITDA has dropped by -$159.48 million (-85.05%).
- PCRX TTM EBITDA is now -85.05% below its all-time high of $187.51 million, reached on March 31, 2024.
Performance
PCRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
PCRX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -81.2% | -3.1% | -85.0% |
| 3 y3 years | -74.5% | -7.7% | -77.8% |
| 5 y5 years | -5.3% | +77.3% | -17.7% |
PCRX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -81.2% | at low | -44.1% | +129.3% | -85.0% | at low |
| 5 y | 5-year | -81.2% | at low | -44.1% | +129.3% | -85.0% | at low |
| alltime | all time | -81.2% | +156.1% | -44.1% | +129.3% | -85.0% | +146.8% |
PCRX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $33.61M(-33.6%) | $28.03M(-3.8%) |
| Dec 2024 | $29.12M(-81.2%) | $50.60M(-144.1%) | $29.12M(-12.9%) |
| Sep 2024 | - | -$114.75M(-295.9%) | $33.42M(-82.0%) |
| Jun 2024 | - | $58.57M(+68.8%) | $185.99M(-0.8%) |
| Mar 2024 | - | $34.70M(-36.8%) | $187.51M(+21.3%) |
| Dec 2023 | $154.59M(+10.1%) | $54.91M(+45.2%) | $154.59M(+27.1%) |
| Sep 2023 | - | $37.81M(-37.1%) | $121.61M(+5.7%) |
| Jun 2023 | - | $60.08M(+3275.4%) | $115.02M(+8.7%) |
| Mar 2023 | - | $1.78M(-91.9%) | $105.77M(-24.7%) |
| Dec 2022 | $140.38M(+23.2%) | $21.93M(-29.7%) | $140.38M(+4.0%) |
| Sep 2022 | - | $31.22M(-38.6%) | $134.96M(-3.9%) |
| Jun 2022 | - | $50.83M(+39.7%) | $140.37M(+11.0%) |
| Mar 2022 | - | $36.39M(+120.3%) | $126.45M(+11.0%) |
| Dec 2021 | $113.95M(+79.4%) | $16.52M(-54.9%) | $113.95M(-6.3%) |
| Sep 2021 | - | $36.63M(-0.8%) | $121.61M(+18.4%) |
| Jun 2021 | - | $36.91M(+54.5%) | $102.67M(+50.0%) |
| Mar 2021 | - | $23.89M(-1.2%) | $68.45M(+7.8%) |
| Dec 2020 | $63.51M(+106.5%) | $24.17M(+36.6%) | $63.51M(+36.7%) |
| Sep 2020 | - | $17.69M(+557.6%) | $46.45M(+36.4%) |
| Jun 2020 | - | $2.69M(-85.8%) | $34.06M(-21.2%) |
| Mar 2020 | - | $18.96M(+166.6%) | $43.23M(+40.6%) |
| Dec 2019 | $30.75M(-7.0%) | $7.11M(+34.2%) | $30.75M(-25.6%) |
| Sep 2019 | - | $5.30M(-55.3%) | $41.35M(-6.2%) |
| Jun 2019 | - | $11.86M(+83.2%) | $44.08M(+3.3%) |
| Mar 2019 | - | $6.48M(-63.4%) | $42.66M(+29.1%) |
| Dec 2018 | $33.05M(-376.1%) | $17.71M(+120.5%) | $33.06M(+16.6%) |
| Sep 2018 | - | $8.03M(-23.0%) | $28.34M(+35.9%) |
| Jun 2018 | - | $10.44M(-433.7%) | $20.85M(-2861.6%) |
| Mar 2018 | - | -$3.13M(-124.1%) | -$755.00K(-93.7%) |
| Dec 2017 | -$11.97M | $13.00M(+2293.6%) | -$11.97M(-50.1%) |
| Sep 2017 | - | $543.00K(-104.9%) | -$24.00M(-42.8%) |
| Jun 2017 | - | -$11.17M(-22.1%) | -$41.94M(+23.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2017 | - | -$14.34M(-1575.7%) | -$33.88M(+83.4%) |
| Dec 2016 | -$18.48M(-189.2%) | $972.00K(-105.6%) | -$18.48M(+7.4%) |
| Sep 2016 | - | -$17.40M(+460.6%) | -$17.21M(-311.2%) |
| Jun 2016 | - | -$3.10M(-393.4%) | $8.14M(-48.7%) |
| Mar 2016 | - | $1.06M(-52.8%) | $15.87M(-23.4%) |
| Dec 2015 | $20.70M(+398.9%) | $2.24M(-71.8%) | $20.70M(-28.7%) |
| Sep 2015 | - | $7.95M(+72.2%) | $29.05M(+29.9%) |
| Jun 2015 | - | $4.62M(-21.7%) | $22.37M(+31.8%) |
| Mar 2015 | - | $5.90M(-44.3%) | $16.97M(+294.1%) |
| Dec 2014 | $4.15M(-108.0%) | $10.58M(+733.3%) | $4.31M(-128.3%) |
| Sep 2014 | - | $1.27M(-262.8%) | -$15.20M(-45.8%) |
| Jun 2014 | - | -$780.00K(-88.5%) | -$28.03M(-26.4%) |
| Mar 2014 | - | -$6.77M(-24.1%) | -$38.08M(-26.7%) |
| Dec 2013 | -$51.94M(+15.9%) | -$8.92M(-22.8%) | -$51.94M(-9.8%) |
| Sep 2013 | - | -$11.56M(+6.7%) | -$57.58M(-3.9%) |
| Jun 2013 | - | -$10.83M(-47.5%) | -$59.89M(+8.0%) |
| Mar 2013 | - | -$20.63M(+41.7%) | -$55.46M(+23.7%) |
| Dec 2012 | -$44.83M(+30.9%) | -$14.56M(+4.9%) | -$44.83M(+3.9%) |
| Sep 2012 | - | -$13.87M(+116.9%) | -$43.15M(+16.7%) |
| Jun 2012 | - | -$6.40M(-36.0%) | -$36.98M(-1.8%) |
| Mar 2012 | - | -$10.00M(-22.4%) | -$37.66M(+11.4%) |
| Dec 2011 | -$34.23M(+79.1%) | -$12.88M(+67.2%) | -$33.79M(+32.2%) |
| Sep 2011 | - | -$7.70M(+8.9%) | -$25.57M(+8.0%) |
| Jun 2011 | - | -$7.08M(+15.4%) | -$23.67M(+11.7%) |
| Mar 2011 | - | -$6.13M(+31.7%) | -$21.19M(+13.6%) |
| Dec 2010 | -$19.12M(-20.7%) | -$4.66M(-19.7%) | -$18.66M(-9.0%) |
| Sep 2010 | - | -$5.80M(+26.3%) | -$20.50M(+3.2%) |
| Jun 2010 | - | -$4.59M(+27.5%) | -$19.86M(+30.1%) |
| Mar 2010 | - | -$3.60M(-44.6%) | -$15.26M(+30.9%) |
| Dec 2009 | -$24.12M(-41.9%) | -$6.50M(+26.1%) | -$11.66M(+126.1%) |
| Sep 2009 | - | -$5.16M | -$5.16M |
| Dec 2008 | -$41.53M | - | - |
FAQ
- What is Pacira BioSciences annual EBITDA?
- What is the all time high annual EBITDA for Pacira BioSciences?
- What is Pacira BioSciences annual EBITDA year-on-year change?
- What is Pacira BioSciences quarterly EBITDA?
- What is the all time high quarterly EBITDA for Pacira BioSciences?
- What is Pacira BioSciences quarterly EBITDA year-on-year change?
- What is Pacira BioSciences TTM EBITDA?
- What is the all time high TTM EBITDA for Pacira BioSciences?
- What is Pacira BioSciences TTM EBITDA year-on-year change?
What is Pacira BioSciences annual EBITDA?
The current annual EBITDA of PCRX is $29.12M
What is the all time high annual EBITDA for Pacira BioSciences?
Pacira BioSciences all-time high annual EBITDA is $154.59M
What is Pacira BioSciences annual EBITDA year-on-year change?
Over the past year, PCRX annual EBITDA has changed by -$125.47M (-81.16%)
What is Pacira BioSciences quarterly EBITDA?
The current quarterly EBITDA of PCRX is $33.61M
What is the all time high quarterly EBITDA for Pacira BioSciences?
Pacira BioSciences all-time high quarterly EBITDA is $60.08M
What is Pacira BioSciences quarterly EBITDA year-on-year change?
Over the past year, PCRX quarterly EBITDA has changed by -$1.09M (-3.15%)
What is Pacira BioSciences TTM EBITDA?
The current TTM EBITDA of PCRX is $28.03M
What is the all time high TTM EBITDA for Pacira BioSciences?
Pacira BioSciences all-time high TTM EBITDA is $187.51M
What is Pacira BioSciences TTM EBITDA year-on-year change?
Over the past year, PCRX TTM EBITDA has changed by -$159.48M (-85.05%)